|Articles|January 27, 2017
Aurinia Selects Worldwide for Phase III Lupus Trial
Aurinia Pharma has announced the selection of Worldwide Clinical Trials as its CRO for the AURORA study.
Advertisement
Aurinia Pharma has announced the selection of Worldwide Clinical Trials as its CRO for the AURORA study, a Phase III clinical trial for the treatment of active lupus nephritis.
Read the full release here
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Ensuring Digital Trial Platforms Work for Underserved Communities
September 10th 2025
- eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
2
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
3
eClinical Technology: Misconceptions, Challenges, and Opportunities
4
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
5